JPRN-jRCT2080222077未知1 期
Phase I/II study of YHI-1001 in combination with Docetaxel in patients with advanced, metastatic or recurrent non-small cell lung cancer who have received platinum-based chemotherapy
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 118
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1)Patients with histologically or cytologically confirmed non-small cell lung cancer
- •(2)Patients who have received platinum-based chemotherapy
- •(3)Patients with ECOG PS of 0-1
- •(4)Patients who are able to take YHI-1001 orally and do not have GI dysfunction impacting on abosorption of YHI-1001
排除标准
- •(1)Patients who have taken HDAC inhibitors or Docetaxel
- •(2)Patients with uncontrolled intercurrent illness
研究者
相似试验
未知
1 期
A phase I/II study in combination of YHI-1001 and Sorafenib in patients with advanced hepatocellular carcinoma previously untreated with systemic chemotherapyJPRN-jRCT2080222078Yakult Honsha Co., Ltd.164
未知
1 期
A phase I study of YHI-1001JPRN-jRCT2080221834Yakult Honsha Co., Ltd.18
未知
1 期
Phase I trial of YHI-1003 plus Bortezomib and DexamethasoneRelapsed Multiple Myeloma previously treated with BortezomibJPRN-jRCT2080221706Yakult Honsha Co., Ltd.18
已完成
2 期
A Phase II Study of YHI-1702JPRN-jRCT2071210133Hiroki Kageyama21
已完成
2 期
A Phase II Study of YHI-1702Follicular lymphomaJPRN-jRCT2031210529Suzuki Kenta36